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Abstract 78 
Context: There has been concern that growth hormone (GH) treatment of children might 79 
increase meningioma risk. Results of published studies have been inconsistent and limited.  80 
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Objective: To examine meningioma risks in relation to GH treatment. 81 
Design: Cohort study with follow-up via cancer registries and other registers. 82 
Setting: Population-based. 83 
Patients: A cohort of 10,403 patients treated in childhood with recombinant GH (r-hGH) in 5 84 
European countries since this treatment was first used in 1984. Expected rates from national 85 
cancer registration statistics. 86 
Main Outcome Measures: Risk of meningioma incidence. 87 
Results: During follow-up 38 meningiomas occurred. Meningioma risk was greatly raised in the 88 
cohort overall (SIR=75.4; 95% confidence interval (CI) 54.9-103.6), as a consequence of high 89 
risk in subjects who had received radiotherapy for underlying malignancy (SIR= 658.4; 95% CI 90 
460.4-941.7). Risk was not significantly raised in patients who did not receive radiotherapy. Risk 91 
in radiotherapy-treated patients was not significantly related to mean daily dose of GH, duration 92 
of GH treatment or cumulative dose of GH.  93 
Conclusions: Our data add to evidence of very high risk of meningioma in patients treated in 94 
childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-95 
related risk, and that there is no material raised risk of meningioma in GH-treated patients who 96 
did not receive radiotherapy.  97 
Introduction 98 
 Since 1957 growth hormone (GH) has been used to treat GH deficiency and short 99 
stature, initially using a human pituitary extract (p-hGH) but since 1985 using solely recombinant 100 
growth hormone (r-hGH). 101 
 GH causes increased serum concentrations of insulin-like growth factor 1 (IGF-1). IGF-1 102 
is antiapoptotic and mitogenic in vitro, and levels in adults have been associated in several 103 
studies with risks of subsequent malignancies(1). As a consequence, and because of early 104 
                                    
5 
 
case-reports and some findings in humans, there has been concern as to whether or not GH 105 
therapy might increase cancer risks(1, 2).  106 
 Meningiomas express GH receptors, and in vitro activation of the GH/IGF-1 axis 107 
increases the growth rate of meningiomas(3). In an in vivo model, downregulation of the 108 
GH/IGF-1 axis reduced meningioma growth(4). In the US Childhood Cancer Survivors Study 109 
cohort, second malignancy was significantly more common among GH-treated than non GH-110 
treated patients, and meningioma was much the most common second malignancy in the GH-111 
treated group, accounting for 40% of all second neoplasms(5). A UK study(6) found 112 
meningiomas more common in GH-treated brain-irradiated cancer patients than in matched 113 
brain-irradiated cancer controls, but based on small numbers, and a later analysis from the US 114 
cohort did not find raised meningioma risk(7). The published results, however, have been based 115 
on relatively small numbers – 338 GH-treated patients in the US study(7) and 110 in the only 116 
other analysis, in the UK(6). To analyse the risk with much greater power, we therefore analysed 117 
meningioma risks in the Safety and Appropriateness of Growth Hormone Treatments in Europe 118 
(SAGhE) study, a large cross-European cohort study of patients treated with r-GH since 1984. 119 
Materials and Methods 120 
 The SAGhE study is a coordinated cohort study in eight European countries of patients 121 
treated with r-hGH at paediatric ages since such treatment was first used (1984-6, depending on 122 
the country), and never treated with p-hGH. Details of the assembly of the cohort and methods 123 
of data collection have been described previously(8). Ethics committee agreement was obtained 124 
in every country and for each patient either written informed consent was obtained, or the ethics 125 
committee stated that consent was not required. Only three patients in the cohort died from 126 
meningioma during follow-up, so we have only undertaken incidence analyses, not mortality 127 
analyses, for meningioma in this paper. Cancer incidence follow-up was via cancer registration 128 
and highly complete in Belgium, the Netherlands, Sweden, Switzerland and the UK, and 129 
therefore analyses of incidence are restricted to these countries. The cohorts were national and 130 
population-based, or virtually so, in Belgium, the Netherlands, Sweden and the UK and clinic-131 
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based and sub-national in (Switzerland). We obtained data on demographic and GH-related 132 
variables from existing databases and from case-notes. Subjects were followed for mortality via 133 
national population-based registries in Belgium, the Netherlands, Sweden and the UK, and by 134 
municipal registers and other means in Switzerland. In all countries, follow-up was independent 135 
of pharmaceutical companies and in all countries the study was conducted with appropriate 136 
ethics committee agreement. Vital status follow-up was highly complete. We excluded from 137 
analysis, individuals with certain conditions that both lead to GH therapy and are themselves 138 
very strong predisposing factors for malignancy (e.g. Type 1 neurofibromatosis, Fanconi 139 
syndrome(9)). In addition, we also excluded from the cohort, subjects (n=1) whose original 140 
diagnosis leading to growth hormone treatment was meningioma.  141 
 We calculated person-years at risk of meningioma in the cohort by sex, 5 year age-142 
group, single calendar year, and country, commencing on the date of first treatment with GH and 143 
ending at whichever occurred earliest of: diagnosis of meningioma, death, loss to follow-up, or a 144 
fixed end-date for each country (the date to which follow-up in that country was considered 145 
complete at the time the follow-up data were obtained). In Switzerland, cancer incidence follow-146 
up was censored at age 16 or 21, depending on the canton, because cancer incidence data 147 
were from the Swiss Childhood Cancer Registry which only covered these ages. 148 
 Meningiomas were taken as tumours coded to ICD10 codes C70 (malignant), D32 149 
(benign) and D42 (uncertain and unknown behaviour) (WHO, 1992), and equivalents in ICD 9. 150 
Observed numbers of cancers and deaths in the cohort were compared with expectations 151 
derived from application of sex, age, country and year specific rates in the general population of 152 
each country to the person-years at risk in these categories in the cohort, to provide 153 
standardised incidence ratios (SIRs). Absolute excess rates (AERs) were calculated by 154 
subtracting expected from observed numbers of cases, dividing by person-years at risk and 155 
multiplying by 10,000. Trends in risk with variables such as duration of GH treatment were tested 156 
as described by Breslow and Day(10); p values are all 2-sided. 157 
                                    
7 
 
 As well as analyses of risks in the cohort overall, we also analysed the data in 158 
subdivisions by initial diagnosis, whether radiotherapy was received, and cumulative dose, mean 159 
daily dose, and duration of GH treatment. To be able to explore potential surveillance bias in the 160 
diagnosis of meningiomas in the cohort, we endeavoured to discover from clinical sources for 161 
each UK patient, the pathway that had led to diagnosis of the meningioma.  162 
Results 163 
 Of 10,786 patients recorded as treated with r-hGH in the five study countries, 257 had to 164 
be excluded from analysis because of lack of permission for cancer incidence follow-up or lack 165 
of data, and 126 because of an underlying diagnosis at high risk of cancer or an underlying 166 
diagnosis of meningioma as the reason for GH treatment. This left 10,403 who formed the study 167 
cohort. Just over half were male and four fifths were aged 5-14 years at first treatment (Table 1). 168 
The most common underlying diagnoses were isolated growth failure (n= 3,952), and 169 
malignancy (n= 1,830).  170 
 During follow-up 326 patients died, 175 were lost to follow-up, 38 were diagnosed with 171 
meningioma (30 benign, 1 malignant, and 7 of uncertain behaviour), and 9,864 survived without 172 
meningioma to the end of the follow-up period. A total of 154,795 person-years at risk were 173 
accrued, an average of 14.9 years per patient. The SIR for meningioma in the cohort overall was 174 
75.4 (95% CI54.9-103.6) (Table 2), and the AER was 2.4 per 10,000 (not in Table). Relative 175 
risks were similar in males and females, and greatly raised in the Netherlands, Sweden and the 176 
UK. There were no cases in Belgium and Switzerland but expecteds were small (0.04 and 0.01 177 
respectively) and 95% CIs included the all-country SIR. All but one of the meningiomas occurred 178 
in patients whose initial diagnosis was cancer (SIR=466.3 (95% CI 337.8-643.5)); the risk was 179 
not significantly raised in patients whose initial diagnosis was not cancer (SIR=2.4 (95% CI 0.3-180 
16.7)). Risks were over 300-fold raised for patients whose initial diagnoses were CNS tumour, 181 
haematological malignancy, or non-CNS solid tumour (Table 2). 182 
 We had information that 1,178 of the patients had received cranio(-spinal) radiotherapy 183 
(all but 13 for cancer), 3,055 had not received cranio(-spinal) radiotherapy, and for 6,170 this 184 
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was not known. Thirty of the 38 meningiomas occurred in the cancer patients known to have 185 
received cranio(-spinal) radiotherapy (Table 3). The relative risk of meningioma for cancer 186 
patients treated with radiotherapy was over 600 (Table 3). The SIR was not related to age at first 187 
GH treatment time since starting treatment, or attained age. There were also no significant 188 
trends in risk with mean daily GH dose duration of treatment, and cumulative dose of GH. Of the 189 
remaining meningioma cases, 7 occurred in patients with unknown radiotherapy status 190 
(SIR=277.5 (95% CI 132.3-582.1); all were in Sweden, for which the databases used for this 191 
study did not include data on radiotherapy to allow them to be included in risk analyses, but on 192 
separate enquiry four had received prior radiotherapy and for three no information on this was 193 
available.  One meningioma occurred among patients without radiotherapy (a patient with Turner 194 
syndrome), for whom risk was not significantly raised. 195 
 Of the 22 meningiomas diagnosed incident in patients in the UK, we were able to obtain 196 
information on the events leading to diagnosis for 14; of these; 9 were diagnosed after 197 
symptomatic presentations and 5 at routine follow-up. 198 
Discussion 199 
 Our analysis of over 10,000 patients treated with GH in childhood showed meningioma 200 
risk over 70-fold, highly significantly, raised in this cohort compared with general population 201 
expectations. This was a consequence of a risk six times greater than this in the subset of 202 
patients who had received GH after treatment for cancer, and within these, greater risk again in 203 
the patients who had received cranio(-spinal) radiotherapy. Although we do not have data on 204 
radiotherapy dose, incidence of GH deficiency after cranial radiotherapy is dose and time 205 
dependent(11-13) and most of the cancer patients had brain tumours, which are usually treated 206 
with 40-50 Gy(11), so we would expect that radiotherapy doses in the cohort will generally have 207 
been ≥40 Gy.  208 
 The relative risks in our cohort for meningioma are far larger than for any other tumour 209 
after GH treatment(9). Since ionizing radiation exposure is a well-established cause of 210 
meningioma(14, 15), including after radiation therapy of childhood cancers(16, 17), the 211 
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extraordinarily large risk in our GH-treated cohort does not in itself incriminate GH. Comparisons 212 
of follow-up of GH-treated and untreated cancer patients in the US and UK(5, 6) have given 213 
some evidence of raised risk of meningioma associated with GH, although a later analysis from 214 
the US cohort(7) did not find raised risk. Our study had the weakness that we were not able to 215 
compare risks in our GH cohort directly with untreated patients, since we did not have data on 216 
such patients.  On the other hand, our study had the strength that we were able, unlike previous 217 
studies, to analyse risks in relation to dose and duration of GH treatment – critical variables in 218 
assessing whether there is an aetiological relationship(18). These GH variables were not 219 
significantly related to meningioma risk and furthermore there was no significant raised risk of 220 
meningioma in the 8,573 non-cancer patients in our cohort who received GH therapy. Thus our 221 
data, based on different variables and a far larger cohort than previously, do not support the 222 
hypothesis that GH treatment influences meningioma risk. We were not able to collect IGF1 data 223 
for the cohort, but future research would be improved by investigating, if practical, whether IGF1 224 
levels during GH treatment relate to subsequent meningioma risk. We were also not able to 225 
analyse meningioma risks in relation to extent of, or treatment for, other pituitary deficiencies, 226 
but these seem unlikely to explain the meningioma risk in these patients since the majority of 227 
cases did not have a record of other pituitary deficiencies and only thirteen had a record of 228 
treatment for such deficiencies. 229 
 230 
 The main reason for the raised meningioma risk in the cohort is likely to be ionising 231 
radiation exposure. Previous cohort studies of meningioma risk after radiation exposure have 232 
found excess relative risks (ERRs) per Gy ranging from 0.64 to 5.1, with a summary ERR across 233 
studies of 1.81(15). Our relative risks are of the same order as those for ≥40 Gy exposures to 234 
the meninges in a large UK childhood cancer cohort(16), but several times larger than those 235 
found in a similar US cohort(17). 236 
 Meningioma is a tumour for which there is known to be a high prevalence of subclinical 237 
disease: on brain MRI in the general population, 0.5% of individuals aged 45-59 (the youngest 238 
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ages studied) had incidental findings of meningioma(19). There is therefore considerable scope 239 
for intensive medical contacts and cerebral imaging (especially MRI) consequent on underlying 240 
cerebral malignancies and GH treatment in our cohort to lead to diagnosis of asymptomatic 241 
meningiomas that would not otherwise have been detected, or at least not at that time. Such a 242 
‘screening’ effect, if there is one, might be expected to operate particularly around (or indeed 243 
before) the time of first treatment with GH, when prevalent asymptomatic meningiomas incident 244 
over many years previously might come to light, and to diminish subsequently, when only newly 245 
incident cases would be available for detection. Our data, however, did not show diminishing 246 
risks with longer time since first treatment. Furthermore, among the UK cases for whom we 247 
could identify the pathway to diagnosis, most of the tumours were investigated because of 248 
symptoms (although we cannot tell, of course, whether these symptoms would not have been 249 
presented, or not have been investigated further, if the patient had not had a previous cerebral 250 
tumour and GH treatment). 251 
 A more subtle screening effect might have occurred if improvements in imaging 252 
technology over time had caused detection of some meningiomas in the cohort in recent years 253 
that were already present but undetected at the time of earlier, lower sensitivity, imaging(6). This 254 
could have led to artefactual raised risks throughout follow-up; we do not have data to measure 255 
the extent, if any, of such an effect. 256 
 In conclusion, our data add to evidence of the very high relative risks of meningioma in 257 
patients treated in childhood with r-hGH after cranial radiotherapy for malignancy. Clinically it is 258 
important to be aware of this risk when following-up such patients. Our data and the previous 259 
literature on radiation effects indicate that the raised risk is mainly due to radiotherapy, although 260 
it may also to some extent reflect detection of asymptomatic meningiomas as a consequence of 261 
intensive medical surveillance and cerebral imaging in these patients. Our data also suggest, 262 
however, that GH treatment has not augmented further the radiotherapy-related risk. 263 
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Table 1. Descriptive characteristics of patients in the SAGhE cohort followed for risk of meningioma 
Characteristic  No.                 % 
   
Sex Male 5530               
4517 
53.2 
Female 873               
3825 
46.8 
    
Country Belgium 1325 12.7 
 Netherlands 1685 16.2 
 Sweden 2822 27.1 
 Switzerland 737 7.1 
 UK 3834 36.9 
    
Age started GH treatment 
(years) 
0-4 1130 10.9 
5-9 3632 34.9 
10-14 4834 46.5 
15-19 807 7.8 
    
Year started GH treatment <1990 2070 19.9 
1990-94 3976 38.2 
1995-99 2840 27.3 
≥2000 1517 14.6 
    
Diagnosis leading to GH 
treatment 
CNS tumour 1307 12.6 
Non CNS solid tumour 97 0.9 
Hematological malignancy 426 4.1 
Chronic renal failure and renal diseases 
 
 
 
 
 
renrenal diseases diseases 
139 1.3 
Turner syndrome 1721 16.5 
Other syndromes and chronic diseases 1003 9.6 
Multiple pituitary hormone deficiency organic 
GHD 
1343 12.9 
Skeletal dysplasias 286 2.8 
Isolated growth failure
a 
3952 38.0 
Non-classifiable 129 1.2 
Total  10403 100.0 
 413 
a
Including isolated growth hormone deficiency, idiopathic short stature, and small for gestational age. 414 
 415 
 416 
 417 
 418 
 419 
 420 
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 421 
Table 2.        Risk of meningioma in the cohort in relation to sex, country of residence, and initial diagnosis leading to GH treatment 
 
    
All initial diagnoses  
 
Initial diagnosis cancer  
 
Initial diagnosis non-cancer 
 
   
n  
 
SIR (95% CI) 
 
 n SIR (95% CI)  n SIR (95% CI) 
Sex 
           
 Male   18  83.7 (52.7, 132.8)
***
  18 464.9 (292.9, 737.8)
***
  0 0.0 (0.0, 20.5) 
 Female   20  69.2 (44.7, 107.3)
***
  19 467.6 (298.3, 733.1)
***
  1 4.0 (0.6, 28.6) 
Country of residence 
           
 Belgium   0  0.0 (0.0, 92.2)  0 0.0 (0.0, 368.9)  0 0.0 (0.0, 92.2) 
 Netherlands   9  84.4 (43.9, 162.2)
***
  9 503.4 (261.9, 967.5)
***
  0 0.0 (0.0, 41.0) 
 Sweden   7  40.5 (19.3, 85.0)
***
  7 385.6 (183.8, 808.8)
***
  0 0.0 (0.0, 24.6) 
 Switzerland   0  0.0 (0.0, 368.9)  0 0.0 (0.0, 6148.1)  0 0.0 (0.0, 368.9) 
 UK   22  126.8 (83.5, 192.6)
***
  21 593.5 (387.0, 910.3)
***
  1 7.2 (1.0, 51.4) 
Diagnosis leading to GH treatment 
      
 CNS tumour   29  533.7 (370.9, 768.0)
***
  29 533.7 (370.9, 768.0)
***
  - - 
 Haematological malignancy   7  319.2 (152.2, 669.5)
***
  7 319.2 (152.2, 669.5)
***
  - - 
 Non-CNS solid tumour   1  324.1 (45.6, 2300.6)
**
  1 324.1 (45.6, 2300.6)
**
  - - 
 Turner syndrome   1  9.2 (1.3, 65.0)
*
  - -  1 9.2 (1.3, 65.0)
*
 
 Isolated growth failure   0  0.0 (0.0, 19.4)  - -  0 0.0 (0.0, 19.4) 
 Other non-cancer   0  0.0 (0.0, 30.7)  - -  0 0.0 (0.0, 30.7) 
            
Total   38  75.4 (54.9, 103.6)
***
  37 466.3 (337.8, 643.5)
***
  1 2.4 (0.3, 16.7) 
 422 
SIR= Standardised incidence ratio; CI= confidence interval; GH= Growth hormone; CNS= central nervous system 423 
*
 p<0.05 424 
** 
p<0.01 425 
***
 p<0.001 426 
 427 
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 428 
Table 3. Risk of meningioma in patients whose initial diagnosis was cancer and were treated 
                                by radiotherapy, by age and GH treatment variables 
 
                        
  n 
 
SIR (95% CI) 
 
   
    
      
Age started GH treatment 
(years) 
0-4  1 1401.5 (197.4, 9949.0)
**
    
5-9  9 782.4 (407.1, 1503.7)
***
    
10-14  19 644.7 (411.2, 1010.7)
***
    
15-19  1 258.1 (36.4, 1832.1)
**
    
 p trend  0.21   
    
Time since started GH 
treatment (years) 
0-4  2 338.0 (84.5, 1351.4)
***
    
5-9  2 197.5 (49.4, 789.5)
***
    
10-14  14 1130.7 (669.7, 1909.2)
***
    
15-19  10 857.0 (461.1, 1592.8)
***
    
 ≥20  2 365.8 (91.5, 1462.5)
***
    
 p trend  0.26   
    
Attained age (years) 0-9  0 0.0 (0.0, 12296.3)    
 10-19  6 487.2 (218.9, 1084.3)
***
    
 20-29  21 863.5 (563.0, 1324.4)
***
    
 ≥30  3 346.7 (111.8, 1074.8)
***
    
 p trend   0.95    
        
Duration of GH treatment 
(years) 
<3  8 547.5 (273.8, 1094.7)
***
    
3-5  11 587.3 (325.3, 1060.5)
***
    
≥6  11 998.9 (553.2, 1803.8)
***
    
 p trend  0.19   
    
Mean GH dose (µg/kg/day) <20  7 635.1 (302.8, 1332.2)
***
    
20-9  17 805.4 (500.7, 1295.6)
***
    
30-9  3 425.1 (137.1, 1318.1)
***
    
≥40  1 1297.5 (182.8, 9210.9)
**
    
 p trend  0.92   
    
Cumulative GH dose 
(mg/kg) 
<25  8 511.9 (256.0, 1023.7)
***
    
25-49  10 601.3 (323.6, 1117.6)
***
    
50-99  11 1286.0 (712.2, 2322.1)
***
    
 
≥100  0 0.0 (0.0, 4098.8)    
 p trend  0.13   
Total  30 658.4 (460.4, 941.7)
***
    
 429 
 430 
SIR= Standardised incidence ratio; CI= Confidence interval; GH= Growth hormone 431 
* 
p<0.05 432 
**
 p<0.01 433 
***
 p<0.001 434 
